FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578328514> ?p ?o ?g. }

• W2578328514 abstract "Mitochondrial dysfunction is associated with obesity and various obesity-associated pathological conditions including glucose intolerance. 5-Aminolevulinic acid (ALA), a precursor of heme metabolites, is a natural amino acid synthesized in the mitochondria, and various types of cytochromes containing heme contribute to aerobic energy metabolism. Thus, ALA might have beneficial effects on the reduction of adiposity and improvement of glucose tolerance through its promotion of heme synthesis. In the present study, we investigated the effects of ALA combined with sodium ferrous citrate (SFC) on obesity and glucose intolerance in diet-induced obese mice. We used 20-weeks-old male C57BL/6J diet-induced obesity (DIO) mice that had been fed high-fat diet from 4th week or wild-type C57BL/6J mice. The DIO mice were orally administered ALA combined with SFC (ALA/SFC) for 6 weeks. At the 4th and 5th week during ALA/SFC administration, mice were fasted for 5 h and overnight, respectively and used for oral glucose tolerance test. After the ALA/SFC administration, the plasma glucose levels, weight of white adipose tissue, and expression levels of mitochondrial oxidative phosphorylation (OXPHOS) complexes were examined. Furthermore, the effects of ALA/SFC on lipid content and glucose uptake were examined in vitro. Oral administration of ALA/SFC for 6 weeks reduced the body weight by about 10% and the weight of white adipose tissues in these animals. In vitro, ALA/SFC reduced lipid content in mouse 3T3-L1 adipocytes in a dose dependent manner, and enhanced glucose uptake in 3T3-L1 adipocytes by 70–90% and rat L6 myoblasts by 30% at 6 h. Additionally, oral administration of ALA/SFC reduced plasma glucose levels and improved glucose tolerance in DIO mice. Furthermore, ALA/SFC enhanced the expression of OXPHOS complexes III, IV, and V by 40–70% in white adipose tissues of DIO mice, improving mitochondrial function. Our findings indicate that ALA/SFC is effective in the reduction of adiposity and improvement of glucose tolerance, and that the induction of mitochondrial OXPHOS complex III, IV, and V by ALA/SFC might be an essential component of the molecular mechanisms underlying these effects. ALA/SFC might be a useful supplement for obesity and obesity-related metabolic disease such as type 2 diabetes mellitus." @default.
• W2578328514 created "2017-01-26" @default.
• W2578328514 creator A5003857344 @default.
• W2578328514 creator A5005480751 @default.
• W2578328514 creator A5005978998 @default.
• W2578328514 creator A5010192144 @default.
• W2578328514 creator A5021593247 @default.
• W2578328514 creator A5029203922 @default.
• W2578328514 creator A5042009785 @default.
• W2578328514 creator A5055960660 @default.
• W2578328514 creator A5064464692 @default.
• W2578328514 creator A5068276051 @default.
• W2578328514 creator A5074986737 @default.
• W2578328514 creator A5079615300 @default.
• W2578328514 creator A5080128982 @default.
• W2578328514 creator A5082848939 @default.
• W2578328514 creator A5090297441 @default.
• W2578328514 date "2017-01-30" @default.
• W2578328514 modified "2023-10-08" @default.
• W2578328514 title "5-aminolevulinic acid combined with ferrous ion reduces adiposity and improves glucose tolerance in diet-induced obese mice via enhancing mitochondrial function" @default.
• W2578328514 cites W11753821 @default.
• W2578328514 cites W1527172876 @default.
• W2578328514 cites W1529447899 @default.
• W2578328514 cites W1738850590 @default.
• W2578328514 cites W1927710737 @default.
• W2578328514 cites W1969408132 @default.
• W2578328514 cites W1979465512 @default.
• W2578328514 cites W1981224218 @default.
• W2578328514 cites W1985461968 @default.
• W2578328514 cites W1996626295 @default.
• W2578328514 cites W2003235864 @default.
• W2578328514 cites W2012736422 @default.
• W2578328514 cites W2017939459 @default.
• W2578328514 cites W2025861439 @default.
• W2578328514 cites W2041737414 @default.
• W2578328514 cites W2042535492 @default.
• W2578328514 cites W2043541600 @default.
• W2578328514 cites W2044329567 @default.
• W2578328514 cites W2045362322 @default.
• W2578328514 cites W2045900396 @default.
• W2578328514 cites W2069649414 @default.
• W2578328514 cites W2071179641 @default.
• W2578328514 cites W2071692398 @default.
• W2578328514 cites W2089606595 @default.
• W2578328514 cites W2091887970 @default.
• W2578328514 cites W2105641300 @default.
• W2578328514 cites W2111651903 @default.
• W2578328514 cites W2119964718 @default.
• W2578328514 cites W2124595203 @default.
• W2578328514 cites W2132099317 @default.
• W2578328514 cites W2140035060 @default.
• W2578328514 cites W2141029854 @default.
• W2578328514 cites W2141692232 @default.
• W2578328514 cites W2148713009 @default.
• W2578328514 cites W2152101492 @default.
• W2578328514 cites W2159844436 @default.
• W2578328514 cites W2166954428 @default.
• W2578328514 cites W2292081941 @default.
• W2578328514 doi "https://doi.org/10.1186/s40360-016-0108-3" @default.
• W2578328514 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5278573" @default.
• W2578328514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28132645" @default.
• W2578328514 hasPublicationYear "2017" @default.
• W2578328514 type Work @default.
• W2578328514 sameAs 2578328514 @default.
• W2578328514 citedByCount "21" @default.
• W2578328514 countsByYear W25783285142017 @default.
• W2578328514 countsByYear W25783285142018 @default.
• W2578328514 countsByYear W25783285142019 @default.
• W2578328514 countsByYear W25783285142020 @default.
• W2578328514 countsByYear W25783285142021 @default.
• W2578328514 countsByYear W25783285142022 @default.
• W2578328514 countsByYear W25783285142023 @default.
• W2578328514 crossrefType "journal-article" @default.
• W2578328514 hasAuthorship W2578328514A5003857344 @default.
• W2578328514 hasAuthorship W2578328514A5005480751 @default.
• W2578328514 hasAuthorship W2578328514A5005978998 @default.
• W2578328514 hasAuthorship W2578328514A5010192144 @default.
• W2578328514 hasAuthorship W2578328514A5021593247 @default.
• W2578328514 hasAuthorship W2578328514A5029203922 @default.
• W2578328514 hasAuthorship W2578328514A5042009785 @default.
• W2578328514 hasAuthorship W2578328514A5055960660 @default.
• W2578328514 hasAuthorship W2578328514A5064464692 @default.
• W2578328514 hasAuthorship W2578328514A5068276051 @default.
• W2578328514 hasAuthorship W2578328514A5074986737 @default.
• W2578328514 hasAuthorship W2578328514A5079615300 @default.
• W2578328514 hasAuthorship W2578328514A5080128982 @default.
• W2578328514 hasAuthorship W2578328514A5082848939 @default.
• W2578328514 hasAuthorship W2578328514A5090297441 @default.
• W2578328514 hasBestOaLocation W25783285141 @default.
• W2578328514 hasConcept C126322002 @default.
• W2578328514 hasConcept C134018914 @default.
• W2578328514 hasConcept C151955695 @default.
• W2578328514 hasConcept C171089720 @default.
• W2578328514 hasConcept C185592680 @default.
• W2578328514 hasConcept C2776151105 @default.
• W2578328514 hasConcept C2777056448 @default.
• W2578328514 hasConcept C2777391703 @default.
• W2578328514 hasConcept C2780833929 @default.
• W2578328514 hasConcept C511355011 @default.
• W2578328514 hasConcept C55493867 @default.

• next